Literature DB >> 12053016

Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.

Giuseppe Molinaro1, Nicole Gervais, Albert Adam.   

Abstract

BACKGROUND: Angioedema has been reported during recombinant tissue plasminogen activator (rtPA) treatment of acute ischemic stroke, often with concomitant use of angiotensin I-converting enzyme inhibitor treatment. Angioedema has been partly attributed to the nonapeptide bradykinin (BK), although its precise role has been poorly documented until now. The purposes of this report are 2-fold. First, we sought to define and characterize the in vitro kinin-forming capacity of rtPA when incubated with human plasma at a concentration within the therapeutic concentration range of rtPA attained in blood in vivo during fibrinolysis. Second, we sought to define the mechanism by which rtPA liberates BK from purified human single-chain high-molecular-weight kininogen, a key constituent of the contact system of plasma and the precursor of BK. SUMMARY OF REPORT: When incubated with human plasma, in the presence of an angiotensin I-converting enzyme inhibitor, rtPA generates BK, which is further metabolized to des-Arg9-BK. The quantity of kinins generated by rtPA is similar to that observed during the activation of the contact system of plasma with a negatively charged surface, suggesting that it is physiologically relevant. The total amount of des-Arg9-BK liberated during the incubation period depends on the aminopeptidase P activity, its main degrading peptidase. Additionally, incubations using purified proteins of the fibrinolytic and the contact system pathways show that the rtPA kinin-forming capacity is mediated by plasmin.
CONCLUSIONS: We conclude that rtPA used in vitro at a therapeutic concentration has the capacity to generate significant quantities of kinins from human plasma. This kinin-forming activity depends on the activation of the fibrinolytic pathway. These data suggest that angioedema associated with rtPA treatment of ischemic stroke results directly from plasmin-mediated release of BK.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053016     DOI: 10.1161/01.str.0000017284.77838.87

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  23 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  Angioedema after tPA: what neurointensivists should know.

Authors:  Jennifer E Fugate; Ejaaz A Kalimullah; Eelco F M Wijdicks
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

3.  Angioedema after rt-PA treatment in acute ischemic stroke may be attended by shock and worsening of stroke outcome.

Authors:  Carlo Scialò; Laura Strada; Cinzia Finocchi; Carlo Gandolfo; Maurizio Balestrino
Journal:  Neurol Sci       Date:  2014-07-23       Impact factor: 3.307

4.  Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke.

Authors:  S T Engelter; F Fluri; C Buitrago-Téllez; S Marsch; A J Steck; S Rüegg; P A Lyrer
Journal:  J Neurol       Date:  2005-09-27       Impact factor: 4.849

5.  Rivaroxaban-Induced Hypersensitivity Syndrome.

Authors:  Charles-Olivier Chiasson; Arnaud Canneva; François-Olivier Roy; Maxime Doré
Journal:  Can J Hosp Pharm       Date:  2017-08-31

6.  Early Acute Ischemic Stroke Management for Pharmacists.

Authors:  Michael Armahizer; Alison Blackman; Michael Plazak; Gretchen M Brophy
Journal:  Hosp Pharm       Date:  2018-08-07

7.  Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.

Authors:  Fabrício Simão; Tuna Ustunkaya; Allen C Clermont; Edward P Feener
Journal:  Blood       Date:  2017-01-27       Impact factor: 22.113

8.  Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.

Authors:  Albert Adam; Nicolas Montpas; David Keire; Anik Désormeaux; Nancy J Brown; François Marceau; Benjamin Westenberger
Journal:  Biomaterials       Date:  2010-04-27       Impact factor: 12.479

9.  [Orolingual angioedema under systemic thrombolysis with rt-PA: an underestimated side effect].

Authors:  C Ottomeyer; C Sick; M G Hennerici; K Szabo
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

10.  Incidence of orolingual angioedema after intravenous thrombolysis for stroke.

Authors:  Bruno Censori; T Partziguian; V Bonito; M Sgarzi; R Riva; D Alimonti; E Agazzi; M Vedovello; B Frigeni; E Venturelli; S La Gioia; V Barcella; L Daleffe; L Longhi; F Ferri; R Cosentini; M R Rottoli
Journal:  Neurol Sci       Date:  2018-08-06       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.